Bukhman Foundation commits $12 million to T1D Fund to fuel next wave of innovation in type 1 diabetes
The Bukhman Foundation has announced a $12 million donation to the T1D Fund: A Breakthrough T1D Venture.
The T1D Fund is the first and largest scaled venture fund established to catalyse the development of type 1 diabetes cure-oriented therapies.
The Bukhman Foundation’s contribution to the T1D Fund is part of its £100 million pledge to advance groundbreaking type 1 diabetes research and treatment worldwide.
Since announcing the pledge earlier this year, the Bukhman Foundation has supported various initiatives in partnership with Diabetes UK, Breakthrough T1D, and most recently the creation of the Bukhman Centre for Research Excellence in Type 1 Diabetes at the University of Oxford.
This transformative gift supports the T1D Fund’s new $150+ million capital raise, endorsing its higher-conviction investment strategy.
The Fund is intensifying its efforts to catalyse investment in transformative cures and increase the volume and pace of type 1 diabetes innovation.
“We are deeply committed to unlocking life-changing breakthroughs for the millions of people living with type 1 diabetes worldwide,” said Anastasia Bukhman, Co-Founder of the Bukhman Foundation.
She added: “Our donation reflects a strong commitment to the type 1 diabetes community, and confidence in the T1D Fund’s investment strategy and world class team driving progress toward treatments, prevention, and, ultimately, a cure.
“We look forward to the continued progress of the fund, building on our existing commitment and decade-long support of Breakthrough T1D.”
The Bukhman Foundation was established in 2023 by Anastasia and Igor Bukhman to help improve lives and generate positive impact to people and their communities. The foundation focuses on type 1 diabetes medical research, supporting open science, long-term collaboration and visionary thinking; and arts and culture, celebrating and expanding access, and helping the next generation of artists and cultural professionals to be represented, be innovative and excel.
In 2025, the foundation announced an historic £100 million pledge over the next 10 years to advance research and advocacy in type 1 diabetes.
By backing innovative projects and fostering collaboration among top researchers, the Bukhman Foundation’s aim is to spearhead efforts to address the unmet needs of millions of people living with type 1 diabetes worldwide.